Novavax Inc (NVAX) is a publicly traded Healthcare sector company. As of July 5, 2026, NVAX trades at $9.74 with a market cap of $1.60B and a P/E ratio of -18.04. NVAX moved +2.85% today. Year to date, NVAX is +44.94%; over the trailing twelve months it is +44.08%. Its 52-week range spans $5.01 to $11.97. Analyst consensus is neutral with an average price target of $12.83. Rallies surfaces NVAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for NVAX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $9.74 |
| Market Cap | $1.60B |
| P/E Ratio | -18.04 |
| EPS | $-0.54 |
| Dividend Yield | 0.11% |
| 52-Week High | $11.97 |
| 52-Week Low | $5.01 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $596.34M |
| Net Income | $-87.83M |
| Gross Margin | 84.97% |
6 analysts cover NVAX: 0 strong buy, 3 buy, 1 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.83.